LEPR Deficiency Obesity, PCSK1 Deficiency Obesity, POMC Deficiency Obesity
Conditions
Brief summary
The purpose of the study was to assess the efficacy of LB54640 in participants with rare genetic disorders of obesity
Detailed description
Patients with obesity due to POMC, PCSK1 or LEPR deficiency will be enrolled to receive LB54640 by oral administration for 16 weeks. After 16 weeks of treatment, the participant may enter a long term extension phase and receive treatment for up to 1 year.
Interventions
DRUGLB54640
LB54640 QD Oral
Sponsors
LG Chem
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This is a study where each participant participates for up to 56 weeks. The study consists up to 7 visits to study center which include a Screening period, treatment period, and a follow-up period. Eligible participants who are willing to enter the long-term extension period and who are judged by the study doctor to have no safety concerns, will continue to receive LB54640 at the same dose level from the treatment period. The long-term extension period will be followed by a follow-up period
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants aged ≥12 years at the time of enrollment and diagnosed with genetic obesity due to POMC, PCSK1, or LEPR deficiency mutations. * Obesity is defined as BMI ≥30 kg/m2 for participants ≥18 years of age or BMI ≥95th percentile for age and gender for participants \<18 years of age.
Exclusion criteria
* Participants with recent (within 2 months, prior to Screening and up to enrollment) intensive diet/exercise regimen that resulted in \>2% weight loss, use of medication to treat obesity (within 3 months of first dose of LB54640 with certain exceptions), or weight loss surgery within 6 months prior to Screening or prior surgery which resulted in \>10% weight loss with no evidence of weight regain are excluded * History of major surgical procedure * Weight loss surgery within the previous 6 months * Any history of a suicide attempt, or any suicidal behavior * HbA1c \>10.9% * Fasting glucose level \>270 mg/dL
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of BMI | From baseline to Week 16 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Frequency and severity of adverse events of special interest (AESI) | From first dose up to Week 52 | — |
| Mean change and mean percentage change from baseline in body weight | From baseline up to Week 52 | — |
| Frequency and severity of adverse events (AE) | From first dose up to Week 52 | — |
| Mean change and mean percentage change from baseline in Hunger Questionnaire Scores | From baseline up to Week 52 | The question will asked using the Hunger Questionnaire. The questionnaire consists of a new 5-item, patient-reported scale assessing major eating-related factors (worst and average hunger, appetite, craving, and satiety). |
| Mean change and mean percentage change from baseline in body composition assessed by dual energy x-ray absorptiometry | From baseline up to Week 52 | Fat mass and lean mass will be measured through dual energy x-ray absorptiometry |
| Mean change and mean percentage change from baseline in waist circumference. | From baseline up to Week 52 | — |
Countries
France, United Kingdom
Contacts
Primary ContactLG CHEM
Outcome results
None listed